Technical Analysis for MYGN - Myriad Genetics, Inc.

Grade Last Price % Change Price Change
B 29.73 1.47% 0.43
MYGN closed up 1.47 percent on Friday, June 11, 2021, on 49 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical MYGN trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Overbought Stochastic Strength 1.47%
Stochastic Reached Overbought Strength 1.71%
Multiple of Ten Bearish Other 1.71%
Outside Day Range Expansion 1.71%
Overbought Stochastic Strength 1.71%
MACD Bullish Centerline Cross Bullish -0.23%
Older End-of-Day Signals for MYGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Myriad Genetics, Inc. Description

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; and assess a patient's risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancer Clinical Medicine Disease Prostate Cancer Genetics Ovarian Cancer Melanoma Multiplex Lab Testing Medical Genetics Biomarker Diagnostic Tests Medical Research Colorectal Cancer Pancreatic Cancer Biomarkers Immunoassay Companion Diagnostic Diagnostic Services Personalized Medicine Whole Blood Breast And Ovarian Cancer Chemical Pathology Uterine Cancer

Is MYGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 33.97
52 Week Low 10.54
Average Volume 497,750
200-Day Moving Average 22.57
50-Day Moving Average 28.48
20-Day Moving Average 28.26
10-Day Moving Average 28.70
Average True Range 1.19
ADX 13.95
+DI 27.43
-DI 16.55
Chandelier Exit (Long, 3 ATRs) 26.52
Chandelier Exit (Short, 3 ATRs) 28.20
Upper Bollinger Bands 30.10
Lower Bollinger Band 26.42
Percent B (%b) 0.9
BandWidth 12.99
MACD Line 0.31
MACD Signal Line 0.08
MACD Histogram 0.229
Fundamentals Value
Market Cap 2.24 Billion
Num Shares 75.2 Million
EPS 0.06
Price-to-Earnings (P/E) Ratio 495.50
Price-to-Sales 2.33
Price-to-Book 1.54
PEG Ratio 1.40
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.37
Resistance 3 (R3) 30.35 30.12 30.26
Resistance 2 (R2) 30.12 29.96 30.13 30.23
Resistance 1 (R1) 29.93 29.86 30.03 29.94 30.19
Pivot Point 29.70 29.70 29.75 29.71 29.70
Support 1 (S1) 29.50 29.54 29.60 29.52 29.27
Support 2 (S2) 29.27 29.44 29.28 29.23
Support 3 (S3) 29.08 29.27 29.20
Support 4 (S4) 29.09